U.S. Food and Drug Administration (FDA) Accepts Bristol Myers Squibb ’s Application for Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

PRINCETON, N.J.--(BUSINESS WIRE)-- March 19, 2021 -- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for mavacamten, an investigational, novel, oral,...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news